KRT19 and neoplasm: Despite there being a large number of potential biomarkers, there is only a limited number of prognostic and diagnostic tumor biomarkers that are approved of (e.g., mammaglobulin, CK19—BC diagnosis; BRCA1 and 2 gene mutations—OC diagnosis) [79].